Cerebral toxoplasmosis developed after unrelated bone marrow transplantation for acute myeloid leukemia
A 16-year-old boy received an unrelated bone marrow transplant while in second remission of acute myeloid leukemia. He suffered from severe oral mucosal complications and had difficulty taking oral drugs such as sulfamethoxazole/trimethoprim (ST). Engraftment was obtained on transplant day 35, and blurred vision and headache appeared around transplant day 60. Funduscopy revealed retinal hemorrhage and macular edema, and an MRI scan of the head revealed a nodular lesion in the left putamen. Toxoplasma gondii was detected by CSF PCR, and cerebral toxoplasmosis was diagnosed. Following therapy with ST and clindamycin, the patient was administered pyrimethamine, sulfadiazine, and leucovorin. Symptoms improved promptly, and CSF PCR was negative 45 days after the start of treatment. Since the prevalence of toxoplasma antibodies increases with age, it is crucial to avoid toxoplasma reactivation by ST after hematopoietic cell transplantation in postpubescent patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 64(2023), 10 vom: 29., Seite 1275-1279 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Hirate, Tomoaki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.11.2023 Date Revised 03.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.64.1275 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364061340 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364061340 | ||
| 003 | DE-627 | ||
| 005 | 20231226094644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.64.1275 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM364061340 | ||
| 035 | |a (NLM)37914240 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Hirate, Tomoaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cerebral toxoplasmosis developed after unrelated bone marrow transplantation for acute myeloid leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 16-year-old boy received an unrelated bone marrow transplant while in second remission of acute myeloid leukemia. He suffered from severe oral mucosal complications and had difficulty taking oral drugs such as sulfamethoxazole/trimethoprim (ST). Engraftment was obtained on transplant day 35, and blurred vision and headache appeared around transplant day 60. Funduscopy revealed retinal hemorrhage and macular edema, and an MRI scan of the head revealed a nodular lesion in the left putamen. Toxoplasma gondii was detected by CSF PCR, and cerebral toxoplasmosis was diagnosed. Following therapy with ST and clindamycin, the patient was administered pyrimethamine, sulfadiazine, and leucovorin. Symptoms improved promptly, and CSF PCR was negative 45 days after the start of treatment. Since the prevalence of toxoplasma antibodies increases with age, it is crucial to avoid toxoplasma reactivation by ST after hematopoietic cell transplantation in postpubescent patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a Cerebral toxoplasmosis | |
| 650 | 4 | |a Toxoplasma gondii | |
| 650 | 4 | |a Unrelated bone marrow transplantation | |
| 650 | 7 | |a Trimethoprim, Sulfamethoxazole Drug Combination |2 NLM | |
| 650 | 7 | |a 8064-90-2 |2 NLM | |
| 700 | 1 | |a Kitazawa, Hironobu |e verfasserin |4 aut | |
| 700 | 1 | |a Sakaguchi, Hirotoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Akita, Nobuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Chihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Kutsuna, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Mikita, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Takehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hama, Asahito |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Nao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 64(2023), 10 vom: 29., Seite 1275-1279 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:10 |g day:29 |g pages:1275-1279 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.64.1275 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2023 |e 10 |b 29 |h 1275-1279 | ||